期刊文献+

HDAC2与乙酰化P53k320在胃癌细胞中的表达及对其疗效的评价 被引量:2

EXPRESSION OF HDAC2 AND ACETYLATED P53k320 IN GASTRIC CANCER CELLS AND EVALUATION OF ITS THERAPEUTIC EFFECT
下载PDF
导出
摘要 目的 探讨胃癌的早期诊断及疗效评价指标。方法 选取胃癌患者130例,取其癌组织和癌旁组织,检测其HDAC2及乙酰化P53^k320阳性表达情况,HDAC2mRNA、HDAC2蛋白、乙酰化P53^k320蛋白表达量。结果 胃癌组织HDAC2阳性表达率高于癌旁组织,乙酰化P53^k320阳性率低于癌旁组织(P <0.01)。胃癌细胞中HDAC2mRNA、HDAC2蛋白表达量均高于癌旁细胞,乙酰化P53k320蛋白表达量低于癌旁细胞(P <0.01)。CR、PR、SD、PD组患者癌组织中HDAC2蛋白表达量呈增高趋势,乙酰化P53k320蛋白表达量呈降低趋势(P <0.01)。结论胃癌细胞中HDAC2、乙酰化P53^k320蛋白表达情况与治疗效果密切相关。 Objective To investigate the early diagnosis and evaluation of curative effect of gastric cancer.Methods A total of 130 patients with gastric cancer were enrolled.The cancer tissues and adjacent tissues were obtained.the expression of HDAC2 and acetylated P53^k320,HDAC2 mRNA,HDAC2 protein and acetylated P53^k320 protein were detected.Results The positive expression rate of HDAC2 in gastric cancer tissues was higher than that in adjacent tissues.The positive rate of acetylated P53^k320 was lower than that in adjacent tissues(P<0.01).The expression of HDAC2 mRNA and HDAC2 protein in gastric cancer cells were higher than those in adjacent cells,and the expression of acetylated P53 k320 protein was lower than that in adjacent cells(P<0.01).The expression of HDAC2 protein in the cancer tissues of CR,PR,SD and PD groups increased,and the expression of acetylated P53^k320 protein decreased(P<0.01).Conclusion The expression of HDAC2 and acetylated P53^k320 protein in gastric cancer cells is closely related to the treatment effect.
作者 田峰 徐建 徐晓光 TIAN feng;XU Jian;XU Xiao-guang(Linyi Central Hospital,Linyi 276400,China)
机构地区 临沂市中心医院
出处 《山东医学高等专科学校学报》 2019年第6期409-412,F0002,共5页 Journal of Shandong Medical College
关键词 组蛋白去乙酰化酶2 乙酰化P53^k320 胃癌细胞 Histone deacetylase 2 Acetylated P53 k320 Gastric cancer cells
  • 相关文献

参考文献2

二级参考文献41

  • 1SJOBLOM T, JONES S, WOOD L D, et al. The consensus coding sequences of human breast and colorectal cancers [J]. Science 2006, 314(5797): 268-274.
  • 2XU W S, PARMIGIANI R B, MARKS P A. Histone deacetylase inhibitors: molecular mechanisms of action [J]. Oncogene 2007, 26(37): 5541-552.
  • 3KOVACS J J, MURPHY P J, GA1LLARD S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent acti'eation of glucocorticoid receptor [J]. Mol Cell, 2005, 18(5): 601-607.
  • 4LI Y, ZHANG X, POLAKIEWICZ R D, et al. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization [J]. J Biol Chem, 2008, 283(19): 12686-1290.
  • 5ZHU P, MART1N E, MENGWASSER J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis [J]. Cancer cell, 2004, 5(5): 455-463.
  • 6KHAN O, LA THANGUE N B. Drug Insight: histone deacetylase inhibitor-based therapies for cntaneou~ T-cell lymphomas. Nature clinical practice [J]. Oncology, 2008, 5(12): 714-726.
  • 7GREGORETTI I V, LEE Y M, GOODSON H V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis [J]. J Mol Biol, 2004, 338(1): 17-31.
  • 8STIMSON L, LA THANGUE N B. Biomarkers for predicting clinical responses to HDAC inhibitors [J]. Cancer Lett, 2009, 280(2): 177-183.
  • 9MONIOT S, WEYAND M, STEEGBORN C. Structures, substrates, and regulators of Mammalian sirtuins- opportunities and challenges for drug development [J]. Front Pharmacol, 2012(3): 16. Doi: 10.3389/fphar.2012.00016.
  • 10MARKS P A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs [J]. Expert Opin Investig Drugs, 2010, 19(9): 1049-1066.

共引文献173

同被引文献31

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部